About Lamellar
Lamellar is a company based in Bellshill (United Kingdom) founded in 2007. Lamellar has raised $18.39 million across 4 funding rounds from investors including Scottish Enterprise, Invesco Perpetual and Invesco. The company has 5 employees as of June 30, 2021. Lamellar operates in a competitive market with competitors including Bausch & Lomb, Kerecis, BONESUPPORT, Sofregen and Arsenal Medical, among others.
- Headquarter Bellshill, United Kingdom
- Employees 5 as on 30 Jun, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lamellar Biomedical Limited
- Date of Incorporation 17 Nov, 2006
- Jurisdiction GLASGOW
-
Annual Revenue
Not available
-
Net Profit
-$2.49 M (USD)9as on Jun 30, 2019
-
EBITDA
Not available
-
Total Equity Funding
$18.39 M (USD)
in 4 rounds
-
Latest Funding Round
$7.46 M (USD), Series C
May 08, 2017
-
Investors
Scottish Enterprise
& 3 more
-
Employee Count
5
as on Jun 30, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Lamellar
Lamellar has successfully raised a total of $18.39M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $7.46 million completed in May 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Lamellar
Lamellar has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Scottish Enterprise, Invesco Perpetual and Invesco.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage Scottish companies are supported with investment and expertise.
|
Locked | Locked | Locked | |
|
Diversified asset management services are offered globally by Invesco.
|
Locked | Locked | Locked | |
|
Business development and leadership training programs are offered to companies.
|
Locked | Locked | Locked |
Investor details for Lamellar
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lamellar
Investment portfolio details for Lamellar
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Lamellar
Detailed financials for Lamellar
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lamellar Comparisons
Peer comparison for Lamellar
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lamellar
Lamellar operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Bausch & Lomb, Kerecis, BONESUPPORT, Sofregen and Arsenal Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Ophthalmic pharmaceuticals and instruments are developed for eye care.
|
|
| Locked | Locked | Locked |
Fish-skin acellular dermal matrix technology is provided for wound treatments.
|
|
| Locked | Locked | Locked |
Injectable synthetic bone substitutes are developed for fracture treatment.
|
|
| Locked | Locked | Locked |
Silk-derived biomaterials are developed for soft tissue repair in surgery.
|
|
| Locked | Locked | Locked |
Polymer-based foams and fibers are developed for medical applications.
|
Detailed competitors of Lamellar
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lamellar
Complete news archive for Lamellar
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lamellar
Lamellar was founded in 2007.
Lamellar is headquartered in Bellshill, United Kingdom. It is registered at Bellshill, Scotland, United Kingdom.
Lamellar is a funded company, having raised a total of $18.39M across 4 funding rounds to date.
As of Jun 30, 2021, the latest employee count at Lamellar is 5.
Lamellar Biomedical provides its proprietary Lamellasome technology which are mimetics of native extra-alveolar lamellar bodies. They work on developing the Class 3 medical devices, Visco-ease for Radiotherapy-Induced Xerostomia (RIX) and Lamell-eye for moderate to severe Dry Eye Disease (DED). Its lead compound, LMS-611, is also being developed as a novel therapy for Cystic Fibrosis and has EU Orphan Drug status for this indication.
Lamellar's top competitors include Bausch & Lomb, Kerecis and BONESUPPORT.
Lamellar has 4 investors. Key investors include Scottish Enterprise, Invesco Perpetual, Invesco, and TRICAPITAL Angels.